128 related articles for article (PubMed ID: 10647808)
1. Interaction between platelet-aggregating response and vasoconstrictive response to platelet activating factor.
Michibayashi T
J Smooth Muscle Res; 1999 Aug; 35(4):111-24. PubMed ID: 10647808
[TBL] [Abstract][Full Text] [Related]
2. Platelet aggregating response to platelet activating factor participates in activation of the 12-lipoxygenase pathway in platelets from rabbits.
Michibayashi T
Int Angiol; 2002 Sep; 21(3):260-7. PubMed ID: 12384648
[TBL] [Abstract][Full Text] [Related]
3. [Vascular responsiveness of platelet activating factor--with special reference to its action in the presence of platelets].
Michibayashi T
J Smooth Muscle Res; 1996 Oct; 32(5):195-202. PubMed ID: 8985919
[TBL] [Abstract][Full Text] [Related]
4. Platelet aggregation and vasoconstriction related to platelet cyclooxygenase and 12-lipoxygenase pathways.
Michibayashi T
J Atheroscler Thromb; 2005; 12(3):154-62. PubMed ID: 16020916
[TBL] [Abstract][Full Text] [Related]
5. Different types of vasocontractile responses to noradrenaline in the presence of platelets with platelet activating factor.
Michibayashi T
J Smooth Muscle Res; 1997 Jun; 33(3):117-26. PubMed ID: 9533823
[TBL] [Abstract][Full Text] [Related]
6. Continuous binding of the PAF molecule to its receptor is necessary for the long-term aggregation of platelets.
Suzuki M; Sugatani J; Ino M; Shimura M; Akiyama M; Yamazaki R; Suzuki Y; Miwa M
Am J Physiol; 1998 Jan; 274(1):C47-57. PubMed ID: 9458712
[TBL] [Abstract][Full Text] [Related]
7. Platelet-activating factor (PAF) inhibitory profile of KO-286011 on blood platelets in vitro and in vivo.
Ostermann G; Hofmann B; Kertscher HP; Till U
Naunyn Schmiedebergs Arch Pharmacol; 1990 Dec; 342(6):713-8. PubMed ID: 2096302
[TBL] [Abstract][Full Text] [Related]
8. 1-O-hexadecyl-2-metoxy-glycero-3-phosphatidylcholine--a methoxy ether lipid inhibiting platelet activating factor-induced platelet aggregation and neutrophil oxidative metabolism.
Le Blanc K; Samuelsson J; Brohult J; Berg A; Palmblad J
Biochem Pharmacol; 1995 May; 49(11):1577-82. PubMed ID: 7786298
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the actions of some platelet-activating factor antagonists on platelets and aortic smooth muscles.
Teng CM; Yu SM; Ko FN; Chen CC; Wang WC; Chen KY; Huang YL; Huang TF
Eur J Pharmacol; 1991 Nov; 205(2):151-6. PubMed ID: 1812005
[TBL] [Abstract][Full Text] [Related]
10. Involvement of platelet-activating factor in the modulation of vascular tone in the isolated perfused rabbit kidney.
Cailleaux S; Lopes-Martins RA; Aimbire F; Cordeiro RS; Tibiriçá E
Naunyn Schmiedebergs Arch Pharmacol; 1999 Jun; 359(6):505-11. PubMed ID: 10431763
[TBL] [Abstract][Full Text] [Related]
11. Vaso-contractile responsiveness of perfused arterial segments to platelet-derived thromboxane A2.
Michibayashi T
J Smooth Muscle Res; 1992 Feb; 28(1):25-33. PubMed ID: 1392129
[TBL] [Abstract][Full Text] [Related]
12. Neurogenic inhibitory action through platelets of platelet activating factor (PAF) on vasoconstrictive responsiveness to pressor agents.
Michibayashi T
Adv Exp Med Biol; 1997; 433():243-7. PubMed ID: 9561145
[No Abstract] [Full Text] [Related]
13. Inhibition of PAF-induced human platelet responses by newly synthesized ether phospholipids.
Ostermann G; Hofmann B; Kertscher HP; Till U
Thromb Res; 1991 Feb; 61(3):261-9. PubMed ID: 2028445
[TBL] [Abstract][Full Text] [Related]
14. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
Maurice DH; Haslam RJ
Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
[TBL] [Abstract][Full Text] [Related]
15. 1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N trimethyl) hexanolamine: an analogue of platelet-activating factor with partial agonist activity.
Grigoriadis G; Stewart AG
Br J Pharmacol; 1991 Sep; 104(1):171-7. PubMed ID: 1664761
[TBL] [Abstract][Full Text] [Related]
16. Histamine release from rabbit platelets by platelet-activating factor (PAF).
Nakahodo K; Saitoh S; Nakamura M; Kosugi T
Arerugi; 1994 Mar; 43(3):501-10. PubMed ID: 7515227
[TBL] [Abstract][Full Text] [Related]
17. Na+/H+ exchange in PAF-stimulated platelets.
Borin ML; Pinelis VG; Azizova OA; Kudinov YV; Markov CM; Cragoe EJ; Khodorov BI
J Lipid Mediat; 1989; 1(5):257-72. PubMed ID: 2562435
[TBL] [Abstract][Full Text] [Related]
18. Involvement of platelet cyclic GMP but not cyclic AMP suppression in leukocyte-dependent platelet adhesion to endothelial cells induced by platelet-activating factor in vitro.
Hirafuji M; Nezu A; Shinoda H; Minami M
Br J Pharmacol; 1996 Jan; 117(2):299-304. PubMed ID: 8789382
[TBL] [Abstract][Full Text] [Related]
19. Platelet-activating factor increases platelet-dependent glycoconjugate secretion from tracheal submucosal gland.
Sasaki T; Shimura S; Ikeda K; Sasaki H; Takishima T
Am J Physiol; 1989 Dec; 257(6 Pt 1):L373-8. PubMed ID: 2692465
[TBL] [Abstract][Full Text] [Related]
20. Effect of indomethacin and dazoxiben on intravascular platelet aggregation in the anaesthetized rabbit.
Honey AC; Lad N; Tuffin DP
Thromb Haemost; 1986 Aug; 56(1):80-5. PubMed ID: 3775692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
